Santhera Expands Biomedica Agreement to Extend AGAMREE® (Vamorolone) Distribution Across Central Asia and the Caucasus
Pratteln, Switzerland, July 13, 2026 - Santhera Pharmaceuticals (SIX: SANN) today announces an expansion of its exclusive distribution agreement with Biomedica for AGAMREE® (vamorolone), extending…
Read the full articleYou might also wanna read
AstraZeneca compra a una farmacéutica de China los derechos de un medicamento pulmonar por 1.900 millones
Se trata de un inhibidor dual de PDE3/4 concebido para proporcionar efectos broncodilatadores y antiinflamatorios simultáneos.
European Commission Expands Approval of Novartis Gene Therapy for Broader SMA Population
As reported on Pharmaceutical Technology, the European Commission has approved Novartis’ gene replacement therapy Itvisma (onasemnogene abep
Sun Pharma gets go-ahead to sell generic semaglutide in South Africa
The approval is to treat Type II diabetes
L'action Sanofi grimpe et vise les 80 € après un feu vert de la FDA
Le laboratoire pharmaceutique tricolore signe l'une des plus fortes progressions du CAC 40 en milieu de matinée. Le mouvement fait suite au
恒瑞医药回应“双艾”组合再次延迟批准上市：未涉及产品安全性及有效性
恒瑞医药公告公司收到美国食品药品监督管理局关于注射用卡瑞利珠单抗联合甲磺酸阿帕替尼片用于不可切除或转移性肝细胞癌患者的一线治疗的生物制品许可申请的完整回复信。这也���“双艾”组合第三次被FDA延迟批准上市。对此，恒瑞医药回应称，“稳步推进国际化是公司的长期发展战略，公司多项创新
SUS adquire tecnologia para produzir principal remédio contra o HIV
O medicamento foi desenvolvido pela ViiV Healthcare, empresa de pesquisa para prevenção e tratamento para HIV pertencente à biofarmacêutica
Comments
Sign in to join the conversation.
No comments yet. Be the first.